Resistin and Cardiovascular Disease

Trends in Cardiovascular Medicine

Volumn 21, Issue 1, 2011, Pages 20-27

  Ding, Qinxue ^a   White, Sharla Powell ^a   Ling, Christina ^b   Zhou, Wei ^a  

^a STANFORD UNIVERSITY   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 12; INTERLEUKIN 6; RESISTIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CELL MIGRATION; CELL PROLIFERATION; CEREBROVASCULAR DISEASE; CONGESTIVE HEART FAILURE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY CALCIFICATION; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE MARKER; HUMAN; INSULIN SENSITIVITY; META ANALYSIS (TOPIC); MORTALITY; NONHUMAN; OXIDATIVE STRESS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; UNSTABLE ANGINA PECTORIS;

ANIMALS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RESISTIN;

EID: 84859504735     PISSN: 10501738     EISSN: 18732615     Source Type: Journal    
DOI: 10.1016/j.tcm.2012.01.004     Document Type: Review

References (52)

1. Baker J.F., Morales M., Qatanani M., et al. Resistin levels in lupus and associations with disease-specific measures, insulin resistance, and coronary calcification. J Rheumatol 2011, 38:2369-2375.
2. Bhalla V., Kalogeropoulos A., Georgiopoulou V., Butler J. Serum resistin: Physiology, pathophysiology and implications for heart failure. Biomark Med 2010, 4:445-452.
3. Bokarewa M., Nagaev I., Dahlberg L., et al. Resistin, an adipokine with potent proinflammatory properties. J Immunol 2005, 174:5789-5795.
4. Chemaly E.R., Hadri L., Zhang S., et al. Long-term in vivo resistin overexpression induces myocardial dysfunction and remodeling in rats. J Mol Cell Cardiol 2011, 51:144-155.
5. Chu S., Ding W., Li K., et al. Plasma resistin associated with myocardium injury in patients with acute coronary syndrome. Circ J 2008, 72:1249-1253.
6. Costandi J., Melone M., Zhao A., Rashid S. Human resistin stimulates hepatic overproduction of atherogenic ApoB-containing lipoprotein particles by enhancing ApoB stability and impairing intracellular insulin signaling. Circ Res 2011, 108:727-742.
7. de Luis D.A., Gonzalez Sagrado M., Conde R., et al. Lack of association of serum resistin levels with metabolic syndrome criteria in obese female patients. Clin Biochem 2011, 44:1280-1283.
8. Ding Q., Chai H., Mahmood N., et al. Matrix metalloproteinases modulated by protein kinase Cε mediate resistin-induced migration of human coronary artery smooth muscle cells. J Vasc Surg 2011, 53:1044-1051.
9. Efstathiou S.P., Tsiakou A.G., Tsioulos D.I., et al. Prognostic significance of plasma resistin levels in patients with atherothrombotic ischemic stroke. Clin Chim Acta 2007, 378:78-85.
10. Gupta V., Singh A.K., Kumar S., et al. Association of circulating resistin with metabolic risk factors in Indian females having metabolic syndrome. Toxicol Int 2011, 18:168-172.
11. Hoefle G., Saely C.H., Risch L., et al. Relationship between the adipose-tissue hormone resistin and coronary artery disease. Clin Chim Acta 2007, 386:1-6.
12. Hu W.L., Qiao S.B., Hou Q., Yuan J.S. Plasma resistin is increased in patients with unstable angina. Chin Med J (Engl) 2007, 120:871-875.
13. Hussain S., Bibi S., Javed Q. Heritability of genetic variants of resistin gene in patients with coronary artery disease: A family-based study. Clin Biochem 2011, 44:618-622.
14. Jamaluddin M.S., Weakley S.M., Yao Q., Chen C. Resistin: Functional roles and therapeutic considerations for cardiovascular disease. Br J Pharmacol 2011, 165:622-632.
15. Kang S., Chemaly E.R., Hajjar R.J., Lebeche D. Resistin promotes cardiac hypertrophy via the AMP-activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) and c-Jun N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathways. J Biol Chem 2011, 286:18465-18473.
16. Katsiki N., Ntaios G., Vemmos K. Stroke, obesity and gender: A review of the literature. Maturitas 2011, 69:239-243.
17. Kielstein J.T., Becker B., Graf S., et al. Increased resistin blood levels are not associated with insulin resistance in patients with renal disease. Am J Kidney Dis 2003, 42:62-66.
18. Kim B.J., Lee S.H., Ryu W.S., et al. Adipocytokines and ischemic stroke: Differential associations between stroke subtypes. J Neurol Sci 2011, 312:117-122.
19. Korah T.E., Ibrahim H.H., Badr E.A., Elshafie M.K. Serum resistin in acute myocardial infarction patients with and without diabetes mellitus. Postgrad Med J 2011, 87:463-467.
20. Kotani K., Adachi S., Tsuzaki K., et al. The association between resistin, high-density lipoprotein cholesterol and carotid atherosclerosis in elderly women with hypertension. Int J Cardiol 2010, 141:193-194.
21. Krecki R., Krzeminska-Pakula M., Peruga J.Z., et al. Elevated resistin opposed to adiponectin or angiogenin plasma levels as a strong, independent predictive factor for the occurrence of major adverse cardiac and cerebrovascular events in patients with stable multivessel coronary artery disease over 1-year follow-up. Med Sci Monit 2011, 17:CR26-CR32.
22. Krysiak R., Sierant M., Marek B., Okopien B. The effect of perindopril and enalapril on plasma resistin levels in normotensive patients with coronary heart disease. Endokrynol Pol 2011, 61:683-690.
23. Lee S.H., Ha J.W., Kim J.S., et al. Plasma adiponectin and resistin levels as predictors of mortality in patients with acute myocardial infarction: Data from infarction prognosis study registry. Coron Artery Dis 2009, 20:33-39.
24. Lim S., Koo B.K., Cho S.W., et al. Association of adiponectin and resistin with cardiovascular events in Korean patients with type 2 diabetes: The Korean atherosclerosis study (KAS): A 42-month prospective study. Atherosclerosis 2008, 196:398-404.
25. Lin X.J., Zhang Y.D., Guan Q.S., et al. Plasma resistin levels and single-nucleotide polymorphisms in resistin gene 5' flanking region in patients with stroke. Chin Med Sci J 2007, 22:27-32.
26. Lubos E., Messow C.M., Schnabel R., et al. Resistin, acute coronary syndrome and prognosis results from the AtheroGene study. Atherosclerosis 2007, 193:121-128.
27. Luc G., Empana J.P., Morange P., et al. Adipocytokines and the risk of coronary heart disease in healthy middle aged men: The PRIME Study. Int J Obes (London) 2010, 34:118-126.
28. Mazaki-Tovi S., Vaisbuch E., Romero R., et al. Hyperresistinemia: A novel feature in systemic infection during human pregnancy. Am J Reprod Immunol 2010, 63:358-369.
29. Nogueiras R., Gallego R., Gualillo O., et al. Resistin is expressed in different rat tissues and is regulated in a tissue- and gender-specific manner. FEBS Lett 2003, 548:21-27.
30. Ohmori R., Momiyama Y., Kato R., et al. Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease. J Am Coll Cardiol 2005, 46:379-380.
31. On Y.K., Park H.K., Hyon M.S., Jeon E.S. Serum resistin as a biological marker for coronary artery disease and restenosis in type 2 diabetic patients. Circ J 2007, 71:868-873.
32. Osawa H., Doi Y., Makino H., et al. Diabetes and hypertension markedly increased the risk of ischemic stroke associated with high serum resistin concentration in a general Japanese population: The Hisayama study. Cardiovasc Diabetol 2009, 8:60.
33. Owens C.D., Kim J.M., Hevelone N.D., et al. Novel adipokines, high molecular weight adiponectin and resistin, are associated with outcomes following lower extremity revascularization with autogenous vein. J Vasc Surg 2010, 51:1152-1159.
34. Piestrzeniewicz K., Luczak K., Komorowski J., et al. Resistin increases with obesity and atherosclerotic risk factors in patients with myocardial infarction. Metabolism 2008, 57:488-493.
35. Pilz S., Weihrauch G., Seelhorst U., et al. Implications of resistin plasma levels in subjects undergoing coronary angiography. Clin Endocrinol (Oxford) 2007, 66:380-386.
36. Pischon T., Bamberger C.M., Kratzsch J., et al. Association of plasma resistin levels with coronary heart disease in women. Obes Res 2005, 13:1764-1771.
37. Qatanani M., Szwergold N.R., Greaves D.R., et al. Macrophage-derived human resistin exacerbates adipose tissue inflammation and insulin resistance in mice. J Clin Invest 2009, 119:531-539.
38. Rajpathak S.N., Kaplan R.C., Wassertheil-Smoller S., et al. Resistin, but not adiponectin and leptin, is associated with the risk of ischemic stroke among postmenopausal women: Results from the Women's Health Initiative. Stroke 2011, 42:857-862.
39. Ruilope L.M., Garcia-Robles R., Moreno B. Obesity, cardiovascular risk and pharmacotherapy. Blood Press 2002, 11:260-262.
40. Schwartz D.R., Lazar M.A. Human resistin: Found in translation from mouse to man. Trends Endocrinol Metab 2011, 22:259-265.
41. Shin H.J., Park S., Yoon S.J., et al. Association between serum resistin and carotid intima media thickness in hypertension patients. Int J Cardiol 2008, 125:79-84.
42. Shyu K.G., Lien L.M., Wang B.W., et al. Resistin contributes to neointimal formation via oxidative stress after vascular injury. Clin Sci (London) 2011, 120:121-129.
43. Silswal N., Singh A.K., Aruna B., et al. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NF-kappaB-dependent pathway. Biochem Biophys Res Commun 2005, 334:1092-1101.
44. Srikanth S., Deedwania P. Primary and secondary prevention strategy for cardiovascular disease in diabetes mellitus. Cardiol Clin 2011, 29:47-70.
45. Stejskal D., Proskova J., Adamovska S., et al. Preliminary experience with resistin assessment in common population. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2002, 146:47-49.
46. Steppan C.M., Bailey S.T., Bhat S., et al. The hormone resistin links obesity to diabetes. Nature 2001, 409:307-312.
47. Tang N.P., Wang L.S., Yang L., et al. A polymorphism in the resistin gene promoter and the risk of coronary artery disease in a Chinese population. Clin Endocrinol (Oxford) 2008, 68:82-87.
48. Tsukahara T., Nakashima E., Watarai A., et al. Polymorphism in resistin promoter region at -420 determines the serum resistin levels and may be a risk marker of stroke in Japanese type 2 diabetic patients. Diabetes Res Clin Pract 2009, 84:179-186.
49. Wang H., Chen D.Y., Cao J., et al. High serum resistin level may be an indicator of the severity of coronary disease in acute coronary syndrome. Chin Med Sci J 2009, 24:161-166.
50. Weikert C., Westphal S., Berger K., et al. Plasma resistin levels and risk of myocardial infarction and ischemic stroke. J Clin Endocrinol Metab 2008, 93:2647-2653.
51. Yaturu S., Daberry R.P., Rains J., Jain S. Resistin and adiponectin levels in subjects with coronary artery disease and type 2 diabetes. Cytokine 2006, 34:219-223.
52. Zhang M.H., Na B., Schiller N.B., Whooley M.A. Resistin, exercise capacity, and inducible ischemia in patients with stable coronary heart disease: Data from the Heart and Soul study. Atherosclerosis 2010, 213:604-610.